MiR-3928, targeting ERBB3, IL-6R, and CDK6, leads to an increase in G1 phase cells and a decrease in S-phase cells, suggesting its possible therapeutic potential to fight osteosarcoma [31]. Here, CDK6 is linked to osteosarcoma.